1College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Xinyang, 464000, People's Republic of China
2Huazhong Agricultural University, Wuhan, 430070, People's Republic of China
3Laboratory of Veterinary Pharmacology and Toxicology, College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Xinyang City, Henan Province, China
*Corresponding Author: Jinni Liu, Laboratory of Veterinary Pharmacology and Toxicology, College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Xinyang City, Henan Province, China, Email: jinniliu@126.com
Online published on 13 August, 2024.
Enrofloxacin is a special antibacterial agent for animals and is a synthetic third-generation fluoroquinolone broad-spectrum antibacterial agent. It has excellent antibacterial effects and is widely used in clinical practice. However, the solubility of enrofloxacin is extremely low and this has greatly limited its clinical use. We assessed progress in overcoming this deficiency by tracking pharmaceutical alterations to enrofloxacin in vivo delivery systems. We used the keywords ‘enrofloxacin’, ‘pharmaceuticals’ and ‘preparations’ to assess relevant literature sources collected in CNKI, Wanfang, Vepsa, China Patent Information Network, PubMed, Web of Science and other domestic and foreign databases from 2010 to 2022 to summarize the research progress of enrofloxacin pharmaceutics. A total of 62 valid literature were retrieved and we found that pharmaceutic technologies successfully were able to increase enrofloxacin solubility, palatability, bioavailability and half-life. The continuous development and promotion of new drug formulations and new materials will give enrofloxacin preparations broad application prospects in veterinary medicine.
Controlled release preparation, Enrofloxacin, Palatability, Preparation, Solubility, Sustained, Targeting
